Patents Issued in October 18, 2016
  • Patent number: 9468598
    Abstract: Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: October 18, 2016
    Assignee: AstraZeneca AB
    Inventors: Rango Dietrich, Klaus Eistetter, Hartmut Ney
  • Patent number: 9468599
    Abstract: The present embodiments relate to topically delivered compounded medications. A transdermal cream may provide the effective topical administration of multiple medications simultaneously; may include low concentrations of local anesthetics, a NSAID, an anticonvulsant, and/or other active ingredients; and may include lidocaine, prilocaine, meloxicam, and lamotrigine and/or topiramate. Alternatively, the transdermal cream may include a lidocaine/prilocaine base cream to which is added a fine powder of one or more ground up medications to form a compounded medication. The compounded medication in powder form may be generated from grinding up tablets of NSAIDs, anticonvulsants, nerve depressants, antidepressants, muscle relaxants, NMDA receptor antagonists, opiate or opioid agonists, and/or other agents. The compounded medication in powder form may include meloxicam, lamotrigine, topiramate, other active ingredients, and DMSO or Sterile Water for Irrigation.
    Type: Grant
    Filed: April 16, 2012
    Date of Patent: October 18, 2016
    Assignee: CMPD LICENSING, LLC
    Inventors: Jay Richard Ray, II, Charles D. Hodge
  • Patent number: 9468600
    Abstract: The present invention is directed to compositions and processes for their use that allow for the delivery of physiologically active agents, using a unique composition containing glycerin and triglycerides in the proper ratio. The composition functions by acting both as a humectant and occlusive agent attracting water, returning the skin surface to a smooth state and holding water and physiologically active agents in place. The presence of both hydrophobic and hydrophilic components of the current invention solubilize the physiologically actives into the complex matrix, keeping the actives on the skin and allowing them to penetrate the skin over time, thus delivering the actives to the blood stream.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: October 18, 2016
    Assignee: DR. HOLMQUIST HEALTHCARE, LLC
    Inventors: C. Scott Danos, Bruce A. Cranner, Anne-Marie T. Karp
  • Patent number: 9468601
    Abstract: In one aspect, a dry formulation for the effective administration of multiple medications simultaneously for one or more ailments may be provided. The dry formulations include one or more of the following actives in combination with pharmaceutically acceptable excipients or additives: a) at least one antibiotic; b) at least one anti-inflammatory steroid; and c) at least one antifungal agent.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: October 18, 2016
    Assignee: CMPD LICENSING, LLC
    Inventor: Jay Richard Ray, II
  • Patent number: 9468602
    Abstract: The present invention refers to a microemulsion formulation suitable for preventing assembly of amphiphilic drug molecules which may cause hypersensitivity reactions and other unwanted side effects.
    Type: Grant
    Filed: January 5, 2010
    Date of Patent: October 18, 2016
    Assignee: AZAD Pharma AG
    Inventors: Fabio Carli, Elisabetta Chiellini, Van Van Khov-Tran, Mihran Baronian
  • Patent number: 9468603
    Abstract: In one embodiment, the present application discloses synthetic LDL nanoparticles comprising mixtures of components selected from the group consisting of phospholipids, triglycerides, cholesterol ester and free cholesterol; optionally further comprising an agent selected from the group consisting of natural antioxidants, ubiquinol and vitamin E, and methods for preparing the synthetic nanoparticles. The disclosed synthetic LDL nanoparticles are capable of selectively delivering lipophilic drugs and prodrugs to cellular targets expressing LDL receptors after intra venous injection.
    Type: Grant
    Filed: September 13, 2014
    Date of Patent: October 18, 2016
    Assignee: ARBOR THERAPEUTICS, LLC
    Inventors: James D. McChesney, Igor Nikoulin, Steve J. Bannister, Douglas L. Rodenburg
  • Patent number: 9468604
    Abstract: In one aspect, pharmaceutical compositions comprising dispersions of an acid-sensitive drug and a neutral dispersion polymer are disclosed. The acid-sensitive drug has improved chemical stability relative to dispersions of the drug and acidic polymers. In another aspect, pharmaceutical compositions of low-solubility drugs and amphiphilic, hydroxy-functional vinyl copolymers are disclosed.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: October 18, 2016
    Assignee: Bend Research, Inc.
    Inventors: Dwayne T. Friesen, Michael J. Gumkowski, Rodney James Ketner, Douglas A. Lorenz, James A. S. Nightingale, Ravi M. Shanker, James B. West
  • Patent number: 9468605
    Abstract: Pharmaceutical compositions and single unit dosage forms of apremilast, i.e., (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as diseases or disorders ameliorated by the inhibition of TNF-? production in mammals.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: October 18, 2016
    Assignee: Celgene Corporation
    Inventors: Darshan K. Parikh, Anil Menon, Anthony Tutino
  • Patent number: 9468606
    Abstract: A powder is disclosed including core/shell particles having an average particle size of less than 1000 microns, each particle contains a liquid core that is substantially free of water and includes A) a polar liquid having a percent surface polarity of at least 24%, an active ingredient, and C) from about 0.1% to about 20% by weight of at least one solubility enhancing agent that is not an active ingredient; and a shell comprising hydrophobic particles. The powder can be used to topically administer the active ingredient to a human or animal.
    Type: Grant
    Filed: March 31, 2014
    Date of Patent: October 18, 2016
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Ying Sun, Jeffrey M. Wu, Ali Fassih
  • Patent number: 9468607
    Abstract: The present invention provides nanoparticles, methods of making the nanoparticles, and methods of using the nanoparticles to deliver therapeutic agents and/or imaging agents.
    Type: Grant
    Filed: October 9, 2008
    Date of Patent: October 18, 2016
    Assignee: WASHINGTON UNIVERSITY
    Inventors: Gregory M. Lanza, Samuel A. Wickline, Dipanjan Pan
  • Patent number: 9468608
    Abstract: The preparation method of radiation-sensitive copolymer carrier for coating radiated nanoparticles and/or chemotherapy drugs includes forming a nanosphere by diselenide block copolymers and DSPE-PEG-biomarkers to coat chemotherapy drugs and/or radiated nanoparticles that can be released from the opened nanosphere by protons penetrating tissue during proton therapy. The treatment effect of proton therapy is enhanced by two ways of using the radiated nanoparticles released from an opened nanosphere to produce nuclear fission with the protons for releasing electrons to destroy cancer cells of tumor and the chemotherapy drugs released from the opened nanosphere for distributing among tissue to kill the cancer cells of the tumor.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: October 18, 2016
    Assignee: INSTITUTE OF NUCLEAR ENERGY RESEARCH
    Inventors: Wuu-Jyh Lin, Ting-Shien Duh, Wei-Ming Li, Ming-Hsin Li
  • Patent number: 9468609
    Abstract: This invention is directed to compositions having synergistic combinations of astaxanthin with a tomato extract lycopene, and optionally with carnosic acid and/or lutein. More specifically, the present invention provides compositions having synergistic combinations of the aforementioned compounds, which may be used, inter alia, to inhibit/suppress inflammation via the suppression of the expression of anti-inflammatory mediators or via the suppression of the secretion of anti-inflammatory mediators from macrophages at a site of inflammation.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: October 18, 2016
    Assignee: LYCORED LTD.
    Inventors: Rachel Levy, Nurit Hadad, Tanya Sedlov, Morris Zelkha
  • Patent number: 9468610
    Abstract: The present invention relates to the treatment of an individual diagnosed with hearing loss comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: October 18, 2016
    Assignee: MERZ PHARMA GmbH & CO. KGaA
    Inventor: Hagen Kruger
  • Patent number: 9468611
    Abstract: The present invention relates to a method of treating psychiatric symptoms in a subject having a NMDA receptor and a NE receptor which includes administering d-methadone, d-methadol, d-alpha-acetylmethadol, l-alpha-acetylmethadol, d-alpha-normethadol, l-alpha-normethadol, pharmaceutically acceptable salts thereof, or mixtures thereof, to the subject under conditions effective for the substance to bind to the NMDA receptor and NE receptor of the subject.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: October 18, 2016
    Assignee: Relmada Therapeutics, Inc.
    Inventors: Paolo L. Manfredi, Charles E. Inturrisi
  • Patent number: 9468612
    Abstract: Fibrotic diseases are characterized by the replacement of healthy tissue with scar tissue and extracellular matrix in response to tissue damage. Here we describe the reduction of extracellular matrix (ECM) deposition, interstitial fibroblasts, interstitial volume, expression of Collagen I mRNA and protein, expression of profibrotic cytokines and macrophage infiltration by Cysteamine treatment.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: October 18, 2016
    Assignee: Seattle Children's Hospital
    Inventors: Allison A. Eddy, Daryl M. Okamura
  • Patent number: 9468613
    Abstract: Methods are provided for using doxorubicin active agents in which reduced host toxicity is observed. Aspects of the methods including administering to a subject an effective amount of a doxorubicin active agent in conjunction with a doxorubicin toxicity-reducing adjuvant, e.g., a nitrone compound, or a nitrone compound in combination with a bisdioxopiperazine compound. Also provided are compositions for use in practicing the subject methods. The methods and compositions find use in a variety of different applications, including in the treatment of a variety of different disease conditions.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: October 18, 2016
    Assignee: Tosk, Inc.
    Inventors: William A. Garland, Brian D. Frenzel
  • Patent number: 9468614
    Abstract: A method of moisturizing while decolonizing mammalian tissue, comprising applying a multi-valent cationic antiseptic composition to the tissue, and applying a moisturizer composition to at least a portion of the same tissue is provided. An oral care kit comprising a composition comprising the multi-valent cationic antiseptic and the moisturizer composition, and a method of moisturizing oral tissue of a patient requiring intubation using the moisturizer composition and an endotracheal tube coated or impregnated with a cationic antiseptic are also provided.
    Type: Grant
    Filed: May 14, 2013
    Date of Patent: October 18, 2016
    Assignee: 3M INNOVATIVE PROPERTIES COMPANY
    Inventors: Katie F. Wlaschin, Alan R. Dombrowski, Matthew T. Scholz, Ranjani V. Parthasarathy
  • Patent number: 9468615
    Abstract: Provided herein are compounds and pharmaceutical compositions for use in the treatment of neuropathic pain and the neuropathic pain syndromes.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: October 18, 2016
    Assignee: Algiax Pharmaceuticals GmbH
    Inventors: Birgit Hasse, Guido Koopmans
  • Patent number: 9468616
    Abstract: Provided herein are a composition for preventing or treating inflammatory diseases or infectious diseases which contains m-3M3FBS or a pharmaceutically available salt thereof as an active ingredient, and health supplements for improving or preventing inflammatory diseases or infectious diseases which contain m-3M3FBS. Since m-3M3FBS has a microbicidal effect, inhibition of apoptosis, and inhibition of LPS-involved signal transduction which enables to effectively treat or prevent inflammatory diseases or infectious diseases, so that it may be effectively used as medicine or health supplements for treating or preventing inflammatory diseases or infectious diseases.
    Type: Grant
    Filed: March 14, 2012
    Date of Patent: October 18, 2016
    Assignee: Research & Business Foundation SUNGKYUNKWAN UNIVERSITY
    Inventors: Yoe Sik Bae, Sang Doo Kim
  • Patent number: 9468617
    Abstract: Topical pharmaceutical gel compositions of diclofenac sodium are provided. The topical gel compositions contain at least about 10% w/w diclofenac sodium and are suitable for once-a-day topical application.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: October 18, 2016
    Assignee: LUPIN ATLANTIS HOLDINGS SA
    Inventor: Bala Chandran Nayar
  • Patent number: 9468618
    Abstract: A topical pharmaceutical gel composition of diclofenac sodium suitable for once-a-day topical application is provided. The topical gel composition contains at least about 10 % w/w of diclofenac sodium and once-a-day application of the composition provides relief from pain or inflammation comparable to that achieved with four times daily application of diclofenac sodium 1 % or 3 % topical gel.
    Type: Grant
    Filed: December 13, 2014
    Date of Patent: October 18, 2016
    Assignee: LUPIN ATLANTIS HOLDINGS SA
    Inventor: Bala Chandran Nayar
  • Patent number: 9468619
    Abstract: The invention regards the use of triiodothyronine sulfate, commonly named T3S, as a medicament having thyromimetic activity for the treatment of pathologies due to organic deficiency of triiodothyronine (T3), as such or in association with thyroxine (T4), and pharmaceutical formulations for oral administration thereof.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: October 18, 2016
    Assignee: Bracco S.P.A.
    Inventors: Aldo Pinchera, Livio Cavalieri, Federico Maisano, Giovanni Rivolta, Ferruccio Santini, Fulvia Vella
  • Patent number: 9468620
    Abstract: The present invention relates to use of DHA analogs and their pharmaceutical compositions for treating ototoxicity, by administering these compounds or pharmaceutical compositions to subjects in need thereof. Ototoxicity is defined as damage to the structures of the ear, such as the cochlea and vestibular system, by drugs or toxins. Ototoxicity can result in irreversible hearing loss, tinnitus, dysequilibrium, Meniere's disease, or vertigo.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: October 18, 2016
    Assignee: Andida Pharma, Inc.
    Inventor: Per Gjorstrup
  • Patent number: 9468621
    Abstract: A metal-salen complex compound responsive drug, which has an antidotal property capable of neutralizing cytotoxicity of a metal-salen complex compound, and an intra-corporeal behavior control system for the metal-salen complex compound are provided. This metal-salen complex compound responsive drug contains an effective amount of a metal chelating agent to suppress side effects by the metal-salen complex compound.
    Type: Grant
    Filed: September 19, 2012
    Date of Patent: October 18, 2016
    Assignees: IHI Corporation
    Inventors: Yoshihiro Ishikawa, Haruki Eguchi
  • Patent number: 9468622
    Abstract: The present invention provides ?-keto peracids and methods for producing and using the same. In particular, ?-keto peracids are useful as antimicrobial agents.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: October 18, 2016
    Assignee: CHD Bioscience, Inc.
    Inventors: Edwin D. Neas, John D. Skinner
  • Patent number: 9468623
    Abstract: The present invention provides compound extracted from Garcinia species and the use of said compound in preventing and treating cancer.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: October 18, 2016
    Assignee: Hong Kong Baptist University
    Inventors: Hong-xi Xu, Yuan-zhi Lao, Zhi-jie Ding, Hong Zhang, Kai-xian Chen, Hong-sheng Tan, Zhao-xiang Bian, Cheng-yuan Lin, Shi-lin Chen, Da-jian Yang, Ai-ping Lu, Albert Sun Chi Chan
  • Patent number: 9468624
    Abstract: A novel small molecule antagonizes two types of acyl homoserine lactone receptors: membrane-bound and cytoplasmic. A focused library of analogs and derivatives of the original antagonist was synthesized. Analog and derivative molecules harbor a range of activities. The novel small molecule and most potent antagonist protects the eukaryote Caenorhabditis elegans from quorum-sensing-mediated killing by the bacterial pathogen Chromobacterium violaceum. The saving of C. elegans demonstrates the use of these molecules as small molecule antimicrobials.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: October 18, 2016
    Assignee: THE TRUSTEES OF PRINCETON UNIVERSITY
    Inventors: Bonnie L. Bassler, Lee R. Swem, Scott M. Ulrich, Colleen T. O'Loughlin
  • Patent number: 9468625
    Abstract: The invention provides organonitro thioether compounds, compositions containing such compounds, isolated organonitro thioether compounds and methods for using such compounds and compositions to treat cancer in a patient. Exemplary organonitro thioether compounds described herein include 2-(3,3-dinitroazetidin-1-yl)-2-oxoethyl thioethers and variants thereof.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: October 18, 2016
    Assignee: EpicentRx, Inc.
    Inventors: Jan Scicinski, Bryan T. Oronsky
  • Patent number: 9468626
    Abstract: Pharmaceutical formulations comprising nanoparticles of melatonin are useful for the treatment of neonatal brain injury.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: October 18, 2016
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Annamaria Soliani Raschini, Akif Emre Türeli, Eva Marie Prinz
  • Patent number: 9468627
    Abstract: The present invention concerns the treatment of serotonergic dysregulation disorders and/or augmentation of serotonin levels in the brain by add-on treatments to serotonin enhancers, and slow-release formulations of 5-hydroxytryptophan (5-HTP) therefor.
    Type: Grant
    Filed: April 19, 2013
    Date of Patent: October 18, 2016
    Assignee: Duke University
    Inventors: Jacob P. R. Jacobsen, Marc G. Caron
  • Patent number: 9468628
    Abstract: Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: October 18, 2016
    Assignee: PHARMAKEA, INC
    Inventors: John Howard Hutchinson, David Lonergan
  • Patent number: 9468629
    Abstract: The present disclosure provides substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes, of Formula I D-M-D??(Formula I) useful as antiviral agents. In certain embodiments disclosed herein M is a group —P-A-P— where A is Certain substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. Pharmaceutical compositions/and combinations containing one or more substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes and a pharmaceutically acceptable carrier are also provided by this disclosure. Methods for treating viral infections, including Hepatitis C viral infections are provided by the disclosure.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: October 18, 2016
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Qiuping Wang, Akihiro Hashimoto, Godwin Pais, Xiangzhu Wang, Venkat Gadhachanda, Avinash Phadke, Milind Deshpande, Dawei Chen
  • Patent number: 9468630
    Abstract: Disclosed herein are methods of treating diseases associated with increased numbers of eosinophils basophils, and/or neutrophils with R(+) pramipexole.
    Type: Grant
    Filed: August 13, 2013
    Date of Patent: October 18, 2016
    Assignee: Knopp Biosciences LLC
    Inventors: Michael E. Bozik, Gregory Hebrank, Wildon Farwell, Thomas Petzinger, Jr., Steven Dworetzky
  • Patent number: 9468631
    Abstract: The subject invention describes a method of use of Ropinirole™ to alleviate and control menopausal symptoms in women, and in particular, hot flashes. The invention describes the use of Ropinirole as a dopamine agonist with affinity for the dopamine D2, D3, or D4 receptors. Ropinirole may also be used to treat menopausal symptoms in conjunction with Tizanidine™ to further reduce the effects menopausal symptoms by providing a sedative and muscle relaxant effect which aids in sleep. The combination of Ropinirole and Tizanidine provides a useful new compound for treatment of menopausal symptoms that are most disruptive to the functioning in activities of daily living.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: October 18, 2016
    Inventor: Robert L. Knobler
  • Patent number: 9468632
    Abstract: The present invention relates to chemical compounds, methods for their discovery, and their therapeutic and research use. In particular, the present invention provides compounds as therapeutic agents against cancer stem cells.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: October 18, 2016
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Ronald Buckanovich, Scott D. Larsen, Kun Yang
  • Patent number: 9468633
    Abstract: A dosage form that provides a controlled release solid dosage form for the oral administration of a central nervous system stimulant, preferably methylphenidate hydrochloride.
    Type: Grant
    Filed: August 20, 2012
    Date of Patent: October 18, 2016
    Assignee: Andrx Pharmaceuticals, Inc.
    Inventors: Manesh Dixit, Chih-Ming Chen, Xiu Xiu Cheng, Jianbo Xie
  • Patent number: 9468634
    Abstract: The invention relates to perhexiline, or a pharmaceutically acceptable salt thereof, for use in the treatment of heart failure, as well as to a method for treating heart failure, which comprises administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said heart failure. The invention further relates to a treatment programme for treating heart failure, which involves the co-use or co-administration of perhexiline with one or more other compounds that are advantageous in treating heart failure or the symptoms thereof.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: October 18, 2016
    Assignee: Heart Metabolics Limited
    Inventors: Houman Ashrafian, Michael Paul Frenneaux
  • Patent number: 9468635
    Abstract: The present invention belongs to the technical field of medicine, relating in particular to: a fused ring compound as represented by Formula (I) for use as a mineralocorticoid receptor antagonist, a pharmaceutically acceptable salt thereof, and an isomer thereof; a preparation method for these compounds; a pharmaceutical preparation containing these compounds; and an application of these compounds, the pharmaceutically acceptable salt thereof, or the isomers thereof in the preparation of medicants for the treatment and/or prevention of kidney injury, cardiovascular diseases such as hypertension, and/or endocrine disease. The definitions of X, Y1, Y2, Y3, R1, R2a, R2b, R3a, R3b, R4, Cy and n are as presented in the description.
    Type: Grant
    Filed: January 7, 2015
    Date of Patent: October 18, 2016
    Assignee: KBP BIOSCIENCES CO., Ltd.
    Inventors: Zhenhua Huang, Jinyuan Wang, Dedong Zhang
  • Patent number: 9468636
    Abstract: The present disclosure provides an extended release pharmaceutical composition comprising oxycodone and acetaminophen that provides a rapid onset of analgesia, and reduced levels of acetaminophen near the end of the dosing interval. Also provided are methods for reducing the risk of acetaminophen-induced hepatic damage in a subject being treated with an acetaminophen containing composition, as well as methods for treating pain in a subject in need thereof.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: October 18, 2016
    Assignee: MALLINCKRODT LLC
    Inventors: Krishna R. Devarakonda, Michael J. Giuliani, Vishal K. Gupta, Ralph A. Heasley, Susan Shelby
  • Patent number: 9468637
    Abstract: The present invention relates to a new use of phosphodiesterase 1 (PDE1) inhibitors for the treatment of psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder, delusional disorder, mania, or bipolar disorder.
    Type: Grant
    Filed: May 13, 2010
    Date of Patent: October 18, 2016
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Allen A. Fienberg, Lawrence P. Wennogle, Sharon Mates
  • Patent number: 9468638
    Abstract: Provided herein is a pharmaceutical injectable formulation of itraconazole (10 mg/g) where the formulation comprises a solubilizer, a nonionic surfactant/emulsifier, a co-surfactant and a stabilizer. Further provided is a pharmaceutical formulation of itraconazole, said formulation comprising a solubilizer in a concentration of from about 20% to about 75%, a nonionic surfactant/emulsifier in a concentration of from about 20% to about 50%, a co-surfactant in a concentration from about 10% to about 45% and a stabilizer in a concentration of from about 1% to about 15%.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: October 18, 2016
    Assignee: Texas Southern University
    Inventors: Dong Liang, Lei Wu, Mathew Kizhakkekara Joseph, Jyothy Anie John
  • Patent number: 9468639
    Abstract: The invention relates to the use of flibanserin, or a pharmaceutically acceptable acid addition salt thereof, for the treatment of disorders of sexual desire.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: October 18, 2016
    Assignee: Sprout Pharmaceuticals, Inc.
    Inventors: Franco Borsini, Kenneth Robert Evans
  • Patent number: 9468640
    Abstract: The present invention relates to compounds that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect without motor side effects.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: October 18, 2016
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Marcel Frans Leopold De Bruyn, Gregor James Macdonald, Ludo Edmond Josephine Kennis, Xavier Jean Michel Langlois, Frans Alfons Maria Van den Keybus, Yves Emiel Maria Van Roosbroeck
  • Patent number: 9468641
    Abstract: Disclosed herein is an anti-inflammatory pharmaceutical composition comprising a benzopyranyl tetracycle compound represented by Chemical Formula 1 as an active ingredient. The compound exhibits excellent anti-inflammatory activity by perturbing the post-translational modification of the inflammation mediator HMGB, and thus finds applications in pharmaceutical compositions superior in the treatment or prevention of inflammation-related diseases.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: October 18, 2016
    Assignees: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, KYUNGPOOK NATIONAL UNIVERSITY HOSPITAL
    Inventors: Seung Bum Park, Sanghee Lee, Ja Young Koo, Donghyun Lim, Jongmin Park, Kyoungho Suk, Youngpyo Nam
  • Patent number: 9468642
    Abstract: The present invention relates to imidazopyrazine compounds of general Formula (I): in which X, R1, R2, R3a, R3b, R4a, R4b, R4C, and R4D are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: October 18, 2016
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Ulrich Klar, Marcus Koppitz, Dirk Kosemund, Rolf Bohlmann, Benjamin Bader, Philip Lienau, Gerhard Siemeister, Stefan Prechtl, Duy Nguyen, William Scott
  • Patent number: 9468643
    Abstract: The invention features methods and compositions featuring a PDE5 inhibitor for treating or preventing immunological-mediated disease in a subject.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: October 18, 2016
    Assignee: The Johns Hopkins University
    Inventors: Ivan M. Borrello, Paolo Serafini, Kimberly A. Noonan, Vincenzo Bronte
  • Patent number: 9468644
    Abstract: Suggested is a non-therapeutic aqueous composition for topical application, comprising (a) at least one solid active agent having at 20° C. a solubility in water (20° dH) of less than 5 g/L; (b) at least one 1,2-alkandiol having 4 to 12 carbon atoms; and (c) at least one aliphatic alcohol having 2 to 4 carbon atoms.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: October 18, 2016
    Assignee: Symrise AG
    Inventor: Cecile Kalem
  • Patent number: 9468645
    Abstract: The invention provides nutritional supplements, in powder, tablet or capsule dosage forms and aqueous formulations, containing one or more of the purine bioactive compounds described including theacrine and theacrine species.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: October 18, 2016
    Inventor: Jack Owoc
  • Patent number: 9468646
    Abstract: The invention is based on the finding that an increased daily dose of Efavirenz should be used for the treatment of cancer compared to the daily dose used in the treatment of AIDS. The invention thus relates to the use of Efavirenz for preparing a medicament intended for the treatment of cancer, wherein Efavirenz is administered at a dose generating an Efavirenz plasma concentration in said patient superior to 3000 ng/ml. It further relates to the use of Efavirenz for preparing a medicament intended for the treatment of cancer, wherein Efavirenz is administered at a daily dose of at least 1800 mg, in particular between 1800 and 2200 mg. It also relates to the use of Efavirenz for preparing a medicament intended for the treatment of cancer, in which the daily dose of Efavirenz is optimized after administration of a preliminary daily dose and measure or Efavirenz plasma concentration.
    Type: Grant
    Filed: January 23, 2013
    Date of Patent: October 18, 2016
    Assignee: ALIENOR FARMA
    Inventors: Pier Vincenzo Piazza, Nadine Houede, Audrey Laroche-Clary
  • Patent number: 9468647
    Abstract: Endometriosis, including endometriosis externa, endometrioma, adenomyosis, adenomyomas, adenomyotic nodules of the uterosacral ligaments, and endometriotic nodules, such as scar endometriosis are effectively treated by the intralesional administration, including transvaginal, endoscopic or open surgical administration including via laparotomy, of a progestogen. Compositions therefor also are provided.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: October 18, 2016
    Assignee: MISCON TRADING S.A.
    Inventor: Mirudhubashini Govindarajan